Biogen isn’t concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says

[cafead]

via

• Biogen said it is not worried about competing with Eli Lilly as they both try to roll out drugs to treat the early stages of Alzheimer’s disease.
• Biogen CEO Christopher Viehbacher said Eli Lilly’s decision to stop dosing the drug after it clears a certain amount of toxic amyloid brain plaque in a patient may not be the best approach.
• Eli Lilly and Biogen may need to consider rolling out maintenance doses that will keep brain plaque levels low, the executive said during a Q1 2023 earnings call.

article source